CN1220873A - Method for manufacture troche for eliminating gastrointestinal vesicle and its application - Google Patents
Method for manufacture troche for eliminating gastrointestinal vesicle and its application Download PDFInfo
- Publication number
- CN1220873A CN1220873A CN 97122093 CN97122093A CN1220873A CN 1220873 A CN1220873 A CN 1220873A CN 97122093 CN97122093 CN 97122093 CN 97122093 A CN97122093 A CN 97122093A CN 1220873 A CN1220873 A CN 1220873A
- Authority
- CN
- China
- Prior art keywords
- troche
- vesicle
- gastrointestinal
- manufacture method
- eliminating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A method for preparing the defoaming lozenge for stomach and intestine features that the non-active compoents including absorbent, disintegrating agent, lubricant, diluent and/or binder are pressed to form raw lozenge and the raw lozenge is then immersed in the active medicine to suck it. The finished defoaming lozenge has greatly increased its disintegrating and releasing speed of active components, resulting in higher curative effect without additional cost and investment.
Description
The present invention relates to the pharmaceutical technology field, refer in particular to a kind of manufacture method and application thereof of troche for eliminating gastrointestinal vesicle.
The manufacture method of traditional lozenge medicine is with active pharmaceutical ingredients and nonactive pharmaceutical compositions such as excipient etc., and directly mix homogeneously is made ingot again, or when system ingot or whole ingot the mixed active pharmaceutical compositions.When making lozenge, owing to added nonactive composition such as excipient, can overcome the not good enough defective of liquor taste, but because traditional method for making, active pharmaceutical ingredients is mixed among the excipient, it is discharged slowly, not as liquor absorbs easily, drug effect is relatively poor.The gastrointestinal froth breaking medicine that the present invention relates to is poly-disilane (Dimethylpolysiloxane) or dimethylamino silane and silica mixture (Simethicon) or its mixture, has the interfacial activity effect, surface tension is reduced, the effect that gastrointestinal is had froth breaking, be usually used in treating distended tummy or the preceding defoamer of gastrointestinal endoscopy, but because its mouthfeel bitterness, liquid difficulty is used for a mouthful newspaper, it is oral that the inactive excipient of normal adding etc. is made lozenge, but because the lozenge made from conventional method is mixed in active pharmaceutical ingredients among the excipient, its disintegrate and release ratio are slower, so the froth breaking effect is not good enough.
The object of the present invention is to provide a kind of manufacture method of gastrointestinal froth breaking ingot system, comprise earlier inactive excipient etc. is made blank lozenge, again blank lozenge dipping is absorbed the gastrointestinal froth breaking active medicine of fixed amount, improve the disintegrate and the rate of release of gastrointestinal froth breaking medicine, reach the purpose that improves curative effect.
Another object of the present invention is to provide the application technology of this manufacture method, be used to make the manufacture method of other quick-acting lozenge medicines of needs.
The object of the present invention is achieved like this: a kind of manufacture method of troche for eliminating gastrointestinal vesicle, it is characterized in that this manufacture method be earlier nonactive composition comprised absorbent, collapse powder, lubricant, diluent and/or bonding agent be pressed into blank lozenge, should flood the gastrointestinal froth breaking active medicine that absorbs fixed amount by blank lozenge again, make troche for eliminating gastrointestinal vesicle.
This gastrointestinal froth breaking active medicine is the mixture of poly-dimethylamino silane and/or dimethylamino silane and silicon dioxide.
The content of this gastrointestinal froth breaking active medicine is the 1-25 parts by weight.
This absorbent is a silicon dioxide.
This collapses powder and comprises carboxymethyl starch sodium, sodium carboxymethyl cellulose, carboxymethylcellulose calcium.
This lubricant comprises Pulvis Talci, stearic acid, magnesium stearate.
This diluent is monosaccharide or polysaccharide, comprises glucose, galactose, fructose, multitudinous sugar, lactose, mannitol, sorbitol.
This bonding agent comprises the lactose of liquid crystal fiber element or direct compression.
The consisting of of this nonactive composition (parts by weight): absorbent 0.5-5.0, collapse powder 0.5-10.0, lubricant 0.5-5.0, diluent and/or bonding agent 10-80.
The Main Ingredients and Appearance of this troche for eliminating gastrointestinal vesicle and content are (mg): poly-dimethylamino silane 40, silicon dioxide 4, microcrystalline Cellulose 304, carboxymethyl starch sodium 8, Pulvis Talci 4.
The Main Ingredients and Appearance of this troche for eliminating gastrointestinal vesicle and content are (mg): poly-dimethylamino silane 50, silicon dioxide 6, lactose 294, carboxymethyl starch sodium 8, magnesium stearate 4.
The Main Ingredients and Appearance of this troche for eliminating gastrointestinal vesicle and content are (mg): the mixture 60 of dimethylamino silane and silicon dioxide, silicon dioxide 7, microcrystalline Cellulose 244, glucose 244, carboxymethyl starch calcium 16, magnesium stearate 16.
The Main Ingredients and Appearance of this troche for eliminating gastrointestinal vesicle and content are (mg: poly-two silane 80, silicon dioxide 8, microcrystalline Cellulose 391, fructose 97, carboxymethyl starch sodium 12, stearic acid 8.
The Main Ingredients and Appearance of this troche for eliminating gastrointestinal vesicle and content are (mg): mixture 40, silica 12, microcrystalline Cellulose 98, mannitol 390, carboxymethyl starch calcium 26, the magnesium stearate 6 of poly-dimethylamino silane 40, dimethylamino silane and silicon dioxide.
This manufacture method can be used for making quick-acting other lozenge medicines except that troche for eliminating gastrointestinal vesicle of needs.
Need other quick-acting lozenge medicated bags to draw together febrifuge, analgesic, hemorrhage, antibiotic medicine, first aid medicine.
Major advantage of the present invention is:
1, manufacture method of the present invention has changed traditional system ingot production method, create and earlier nonactive compositions such as excipient are made blank lozenge, again blank lozenge dipping is absorbed the manufacture method of the active drug of fixed amount, improve the disintegrate and the rate of release of active medicine greatly with the lozenge medicine of method manufacturing of the present invention, significantly improved the curative effect of medicine.
2, manufacture method of the present invention can also be used to make the lozenge of the quick-acting treatment various diseases of needs except being used to make the troche for eliminating gastrointestinal vesicle, and does not need to increase equipment investment and production cost, is a kind of brand-new manufacturing process technology.
3, control the content of active pharmaceutical ingredients in the manufacture method of the present invention easily, the pained medicine of suiting one's taste, desire reduces the content of its active medicine, only needs to adopt centrifugal method just can remove unnecessary active pharmaceutical ingredients, and is very convenient.
The present invention is further described below in conjunction with preferred embodiment:
Embodiment 1
With bonding agent microcrystalline cellulose etc. 3049, collapse powder 8g and absorbent silicon dioxide 4g mix homogeneously, sieve (30 order) removes coarse granule, adds lubricant Pulvis Talci 4g and puts into mixer mixing 5 minutes together, makes blank lozenge with Ingot pressing machine; Above-mentioned blank lozenge be impregnated in the poly-dimethylamino silane 40g of gastrointestinal froth breaking active medicine, make to absorb poly-dimethylamino silane, make troche for eliminating gastrointestinal vesicle.
For preventing blank lozenge dipping absorbing activity overdose, cause the mouthfeel bitterness, can adopt centrifugal method to remove the active medicine of excess, keep specific active medicine content, very convenient.
Embodiment 2
The Main Ingredients and Appearance of troche for eliminating gastrointestinal vesicle and content are (mg) in the present embodiment:
Gastrointestinal froth breaking active medicine is poly-dimethylamino silane 50
Absorbent is a silicon dioxide 6
Bonding agent is a lactose 294
Collapsing powder is carboxymethyl starch sodium 8
Lubricant is a magnesium stearate 4
Its manufacture method is identical with embodiment 1, so do not repeat.
Embodiment 3
The Main Ingredients and Appearance of troche for eliminating gastrointestinal vesicle and content are (mg) in the present embodiment:
Gastrointestinal active defoaming agent medicine is the mixture (Simethicon) 60 of dimethylamino silane and silicon dioxide
Absorbent is a silicon dioxide 7
Bonding agent is a microcrystalline Cellulose 244
Diluent is a glucose 244
Collapsing powder is carboxymethylcellulose calcium 16
Lubricant is a magnesium stearate 16
Its manufacture method is identical with embodiment 1, so do not repeat.
Embodiment 4
The Main Ingredients and Appearance of troche for eliminating gastrointestinal vesicle and content (mg) in the present embodiment:
Gastrointestinal active defoaming agent medicine is poly-dimethylamino silane 80
Absorbent is a silicon dioxide 8
Bonding agent is a microcrystalline Cellulose 391
Diluent is a fructose 97
Collapsing powder is sodium carboxymethyl cellulose 12
Lubricant is a stearic acid 8
Its manufacture method is identical with embodiment 1, so do not repeat.
Embodiment 5
The Main Ingredients and Appearance of troche for eliminating gastrointestinal vesicle and content (mg) in the present embodiment:
Gastrointestinal active defoaming agent medicine is the mixture 40 of poly-dimethylamino silane 40 and dimethylamino silane and silicon dioxide
Absorbent is a silica 12
Bonding agent is a microcrystalline Cellulose 98
Diluent is a mannitol 390
Collapsing powder is carboxymethylcellulose calcium 26
Lubricant is a magnesium stearate 6
Its manufacture method is identical with embodiment 1, so do not repeat.
The performance of product of the present invention and curative effect, the medicament that will have identical proportioning is tested its outward appearance, hardness, collapsibility and defoaming respectively with the lozenge of above-mentioned manufacture method manufacturing and the lozenge of manufacture method manufacturing commonly used, and test result sees Table 1: table 1
Wherein: I is for making ingot again behind nonactive and the active medicine mix homogeneously;
Mixed active pharmaceutical compositions when II is the system ingot;
III is a mixed active pharmaceutical compositions when putting in order ingot; Can clearly see following result from experimental data:
1, product of the present invention has gloss, and the product tarnish that common method is made;
2, product of the present invention collapses the product that the time of loosing makes well below common method, only uses 92 seconds, and the shortest need of common method 424 seconds, the longest is 805 seconds.
3, product foam time of the present invention is 15 seconds, and the product foam time that common method is made is all more than 120 seconds.
Conclusion is disintegrate and the rate of release that product of the present invention improves medicine greatly, reaches the purpose that improves curative effect.
Manufacture method of the present invention, can also be generalized to manufacturing needs other quick-acting lozenge medicines, for example febrifuge analgesic, antibiotic medicine, first aid medicine etc.Thereby the disintegrate and the rate of release that can improve medicine equally greatly improve the effect of curing the disease.
Claims (16)
1, a kind of manufacture method of troche for eliminating gastrointestinal vesicle, it is characterized in that this manufacture method be earlier nonactive composition comprised absorbent, collapse powder, lubricant, diluent and/or bonding agent be pressed into blank lozenge, should flood the gastrointestinal froth breaking active medicine that absorbs fixed amount by blank lozenge again, make troche for eliminating gastrointestinal vesicle.
2, the manufacture method of troche for eliminating gastrointestinal vesicle as claimed in claim 1 is characterized in that: this gastrointestinal froth breaking active medicine is the mixture of poly-dimethylamino silane and/or dimethylamino silane and silicon dioxide.
3, the manufacture method of troche for eliminating gastrointestinal vesicle as claimed in claim 2 is characterized in that: the content of this gastrointestinal froth breaking active medicine is the 1-25 parts by weight.
4, the manufacture method of troche for eliminating gastrointestinal vesicle as claimed in claim 1 is characterized in that: this absorbent is a silicon dioxide.
5, the manufacture method of troche for eliminating gastrointestinal vesicle as claimed in claim 1 is characterized in that: this collapses powder and comprises carboxymethyl starch sodium, sodium carboxymethyl cellulose, carboxymethylcellulose calcium.
6, the manufacture method of troche for eliminating gastrointestinal vesicle as claimed in claim 1 is characterized in that: this lubricant comprises Pulvis Talci, stearic acid, magnesium stearate.
7, the manufacture method of troche for eliminating gastrointestinal vesicle as claimed in claim 1 is characterized in that: this diluent is monosaccharide or polysaccharide, comprises glucose, galactose, fructose, multitudinous sugar, lactose, mannitol, sorbitol.
8, the manufacture method of troche for eliminating gastrointestinal vesicle as claimed in claim 1 is characterized in that: this bonding agent comprises the lactose of liquid crystal fiber element or direct compression.
9, the manufacture method of troche for eliminating gastrointestinal vesicle as claimed in claim 1 is characterized in that: the consisting of of this nonactive composition (parts by weight): absorbent 0.5-5.0, collapse powder 0.5-10.0, lubricant 0.5-5.0, diluent and/or bonding agent 10-80.
10, the manufacture method of troche for eliminating gastrointestinal vesicle as claimed in claim 1 is characterized in that: the Main Ingredients and Appearance of this troche for eliminating gastrointestinal vesicle and content are (mg): poly-dimethylamino silane 40, silicon dioxide 4, microcrystalline Cellulose 304, carboxymethyl starch sodium 8, Pulvis Talci 4.
11, the manufacture method of troche for eliminating gastrointestinal vesicle as claimed in claim 1 is characterized in that: the Main Ingredients and Appearance of this troche for eliminating gastrointestinal vesicle and content are (mg): poly-dimethylamino silane 50, silicon dioxide 6, lactose 294, carboxymethyl starch sodium 8, magnesium stearate 4.
12, the manufacture method of troche for eliminating gastrointestinal vesicle as claimed in claim 1 is characterized in that: the Main Ingredients and Appearance of this troche for eliminating gastrointestinal vesicle and content are (mg): the mixture 60 of dimethylamino silane and silicon dioxide, silicon dioxide 7, microcrystalline Cellulose 244, glucose 244, carboxymethyl starch calcium 16, magnesium stearate 16.
13, the manufacture method of troche for eliminating gastrointestinal vesicle as claimed in claim 1 is characterized in that: the Main Ingredients and Appearance of this troche for eliminating gastrointestinal vesicle and content are (mg); Poly-two silane 80, silicon dioxide 8, microcrystalline Cellulose 391, fructose 97, carboxymethyl starch sodium 12, stearic acid 8.
14, the manufacture method of troche for eliminating gastrointestinal vesicle as claimed in claim 1 is characterized in that: the Main Ingredients and Appearance of this troche for eliminating gastrointestinal vesicle and content are (mg): mixture 40, silica 12, microcrystalline Cellulose 98, mannitol 390, carboxymethyl starch calcium 26, the magnesium stearate 6 of poly-dimethylamino silane 40, dimethylamino silane and silicon dioxide.
15, the application of the manufacture method of troche for eliminating gastrointestinal vesicle as claimed in claim 1 is characterized in that: this manufacture method can be used for making quick-acting other lozenge medicines except that troche for eliminating gastrointestinal vesicle of needs.
16, the application of the manufacture method of troche for eliminating gastrointestinal vesicle as claimed in claim 15 is characterized in that: other quick-acting lozenge medicated bags of needs are drawn together febrifuge, analgesic, hemorrhage, antibiotic medicine, first aid medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN97122093A CN1097456C (en) | 1997-12-22 | 1997-12-22 | Method for manufacture troche for eliminating gastrointestinal vesicle and its application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN97122093A CN1097456C (en) | 1997-12-22 | 1997-12-22 | Method for manufacture troche for eliminating gastrointestinal vesicle and its application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1220873A true CN1220873A (en) | 1999-06-30 |
| CN1097456C CN1097456C (en) | 2003-01-01 |
Family
ID=5176681
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN97122093A Expired - Fee Related CN1097456C (en) | 1997-12-22 | 1997-12-22 | Method for manufacture troche for eliminating gastrointestinal vesicle and its application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1097456C (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106074615A (en) * | 2016-07-27 | 2016-11-09 | 长春呈实健康实业有限公司 | Gastrointestinal hemostasis froth breaking antibacterial and preparation method thereof |
| CN110314134A (en) * | 2019-01-24 | 2019-10-11 | 北京歌斐医疗器械有限公司 | A kind of gastrointestinal endoscopy auxiliary water and preparation method thereof |
| CN110787155A (en) * | 2019-12-06 | 2020-02-14 | 成都恒瑞制药有限公司 | Itopride hydrochloride pharmaceutical composition and preparation method thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2577800B1 (en) * | 1985-02-22 | 1990-09-07 | Grimberg Georges | GASTRO-RESISTANT GALENIC MEDICINE |
| WO1995010290A1 (en) * | 1993-10-13 | 1995-04-20 | Warner-Lambert Company | Antacid pharmaceutical composition |
| AU706351B2 (en) * | 1994-03-18 | 1999-06-17 | Alfred Schmidt | The use of dimeticone as a transport and carrier system and/or drug delivery system |
-
1997
- 1997-12-22 CN CN97122093A patent/CN1097456C/en not_active Expired - Fee Related
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106074615A (en) * | 2016-07-27 | 2016-11-09 | 长春呈实健康实业有限公司 | Gastrointestinal hemostasis froth breaking antibacterial and preparation method thereof |
| CN106074615B (en) * | 2016-07-27 | 2019-12-20 | 长春呈实健康实业有限公司 | Gastrointestinal hemostasis defoaming bacteriostatic agent and preparation method thereof |
| CN110314134A (en) * | 2019-01-24 | 2019-10-11 | 北京歌斐医疗器械有限公司 | A kind of gastrointestinal endoscopy auxiliary water and preparation method thereof |
| CN110787155A (en) * | 2019-12-06 | 2020-02-14 | 成都恒瑞制药有限公司 | Itopride hydrochloride pharmaceutical composition and preparation method thereof |
| CN110787155B (en) * | 2019-12-06 | 2022-08-19 | 成都恒瑞制药有限公司 | Itopride hydrochloride pharmaceutical composition |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1097456C (en) | 2003-01-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1267106C (en) | Simethicone/anhydrous calcium phosphate compositions | |
| CN1536997A (en) | Crystalline composition containing escitalopram | |
| CN1505515A (en) | Oral pharmaceutical composition of cefpodoxime proxetil | |
| CN1839827A (en) | Strontium ranelate chewing tablet and its preparation process | |
| CN101077338A (en) | Nano lanthanum carbonate and orally disintegrating tablet and preparation method | |
| JP4689786B2 (en) | Pharmaceutical preparation and method for producing the same | |
| CN1723905A (en) | Cefdinir oral disintegration tablet, and its prepn. method | |
| CN1220873A (en) | Method for manufacture troche for eliminating gastrointestinal vesicle and its application | |
| CN101053562A (en) | Otilonium bromide capsule | |
| CN1742741A (en) | Medicinal composition containing amino glucose and calcium agent and vitamin D and use thereof | |
| CN1903183A (en) | Dispersion tablets of telbivudine and its prepn. method | |
| CN1682718A (en) | Telmisartan dispersing tablet and its preparing method | |
| CN1615862A (en) | Miglitol oral disintegration tablet for treating diabetes II and its preparing method | |
| CN1724034A (en) | Vagina effervescent tablets contg. callicarpa nudiflora, and its prepn. method | |
| CN1857296A (en) | Medicine composition with roxithromycin and ambroxol hydrochloride as active components and its preparing method and use | |
| CN1506043A (en) | Quickly disintegrating tablet containing cadotril | |
| CN1582927A (en) | Oral disintegrants of nimodipine and their preparation | |
| CN1883507A (en) | An effervescence tablet of cold-treating preparation and preparation method thereof | |
| CN1692909A (en) | Dosmalfate dispersion tablet and its prepn. method | |
| CN1245163C (en) | Puerarin dispersing tablet composition and its preparation method | |
| CN1943562A (en) | Ubenimex dispersion tablet and its preparing method | |
| CN1208050C (en) | Plaster containing an active agent | |
| CN1557319A (en) | Rosuvastatin dispersion tablet and its preparation method | |
| CN1281232C (en) | Method for preparing compound licorice buccal tablet | |
| CN1270721C (en) | Rapid disintegration and rapid dissolution tablet containing kakonein |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 19990630 Assignee: Yung Shin Pharm. Ind. (Kunshan) Co., Ltd. Assignor: Yongxin Medicines and Chemical Reagents Co., Ltd. Contract record no.: 2010990000089 Denomination of invention: Method for manufacture troche for eliminating gastrointestinal vesicle and its application Granted publication date: 20030101 License type: Exclusive License Record date: 20100221 |
|
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20030101 Termination date: 20121222 |